Immunohistochemical α- and β-catenin and E-cadherin expression and their clinicopathological significance in human lung adenocarcinoma

Pathology Research and Practice

Volumn 202, Issue 9, 2006, Pages 639-650

  Nozawa, Nobuyoshi ^a   Hashimoto, Shuichi ^a   Nakashima, Yutaka ^a   Matsuo, Yoshio ^a   Koga, Takaomi ^a   Sugio, Kenji ^a   Niho, Yoshiyuki ^a   Harada, Mine ^a   Sueishi, Katsuo ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

E cadherin catenin complex; Human lung adenocarcinoma; MIB 1 index; Prognostic factor

Indexed keywords

ALPHA CATENIN; BETA CATENIN; KI 67 ANTIGEN; PROTEIN P53; UVOMORULIN;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG CARCINOGENESIS; MALE; PROGNOSIS; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; TISSUE DIFFERENTIATION;

EID: 33747358689     PISSN: 03440338     EISSN: 16180631     Source Type: Journal    
DOI: 10.1016/j.prp.2006.03.007     Document Type: Article

References (52)

1. Andrews N.A., Jones A.S., Helliwell T.R., and Kinsella A.R. Expression of the E-cadherin-catenin cell adhesion complex in primary squamous cell carcinomas of the head and neck and their nodal metastases. Br. J. Cancer 75 (1997) 1474-1480
2. Bremnes R.M., Veve R., Hirsch F.R., and Franklin W.A. The E-cadherin cell-cell adhesion complex and lung cancer invasion metastasis, and prognosis. Lung Cancer 36 (2002) 115-124
3. Bremnes R.M., Veve R., Gabrielson E., Hirsch F.R., Baron A., Bemis L., et al. High-Throughput tissue microarray analysis used to evaluate biology and prognostic significance of the E-cadherin pathway in non-small-cell lung cancer. J. Clin. Oncol. 20 (2002) 2417-2428
4. Burke L., Flieder D.B., Guinee D.G., Brambilla E., Freedman A.N., Bennett W.P., et al. Prognostic implications of molecular and immunohistochemical profiles of the Rb and p53 cell cycle regulatory pathways in primary non-small cell lung carcinoma. Clin. Cancer Res. 11 (2005) 232-241
5. Choi Y.S., Shim Y.M., Kim S.H., Son D.S., Lee H.S., Kim G.Y., et al. Prognostic significance of E-cadherin and beta-catenin in resected stage I non-small cell lung cancer. Eur. J. Cardiothorac. Surg. 24 (2003) 441-449
6. Conacci-Sorrell M., Zhurinsky J., and Ben-Ze'ev A. The cadherin-catenin adhesion system in signaling and cancer. J. Clin. Invest. 109 (2002) 987-991
7. Damalas A., Ben-Ze'ev A., Simcha I., Shtutman M., Leal J.F., Zhurinsky J., et al. Excess beta-catenin promotes accumulation of transcriptionally active p53. EMBO J 18 (1999) 3054-3063
8. Damalas A., Kahan S., Shtutman M., Ben-Ze'ev A., and Oren M. Deregulated beta-catenin induces a p53- and ARF-dependent growth arrest and cooperates with Ras in transformation. EMBO J 20 (2001) 4912-4922
9. Daniel J.M., and Reynolds A.B. Tyrosine phosphorylation and cadherin/catenin function. Bioessays 19 (1997) 883-891
10. Engelse M.A., Hanemaaijer R., Koolwijk P., and van Hinsbergh V.W.M. The fibrinolytic system and matrix metalloproteinase in angiogenesis and tumor progression. Semin. Thromb. Hemost. 30 (2004) 71-82
11. Garcia S., Martini F., De Micco C., Andrac L., Hardwigsen J., Sappa P., et al. Immunoexpression of E-cadherin and -catenin correlates to survival of patients with hepatocellular carcinomas. Int. J. Oncol. 12 (1998) 443-447
12. Ginestra A., La Placa M.D., Saladino F., Cassara D., Nagase H., and Vittorelli M.L. The amount and proteolytic content of vesicles shed by human cancer cell lines correlates with their in vitro invasiveness. Anticancer Res. 18 (1998) 3433-3437
13. Gofuku J., Shiozaki H., Tsujinaka T., Inoue M., Tamura S., Doki Y., et al. Expression of E-cadherin and alpha-catenin in patients with colorectal carcinoma. Correlation with cancer invasion and metastasis. Am. J. Clin. Pathol. 111 (1999) 29-37
14. Gunji N., Oda T., Todoroki T., Kanazawa N., Kawamoto T., Yuzawa K., et al. Pancreatic carcinoma: correlation between E-cadherin and alpha-catenin expression status and liver metastasis. Cancer 82 (1998) 1649-1656
15. Hajra K.M., and Fearon E.R. Cadherin and catenin alterations in human cancer. Genes Chromosomes Cancer 34 (2002) 255-268
16. Hanahan D., and Weinberg R.A. The hallmarks of cancer. Cell 100 (2000) 57-70
17. Hirano S., Kimoto N., Shimoyama Y., Hirohashi S., and Takeichi M. Identification of a neural alpha-catenin as a key regulator of cadherin function and multicellular organization. Cell 70 (1992) 293-301
18. Hommura F., Furuuchi K., Yamazaki K., Ogura S., Kinoshita I., Shimizu M., et al. Increased expression of beta-catenin predicts better prognosis in nonsmall cell lung carcinomas. Cancer 94 (2002) 752-758
19. Huang C.I., Taki T., Higashiyama M., Kohno N., and Miyake M. p16 protein expression is associated with a poor prognosis in squamous cell carcinoma of the lung. Br. J. Cancer 82 (2000) 374-380
20. Ilyas M., and Tomlinson I.P. The interactions of APC, E-cadherin and beta-catenin in tumour development and progression. J. Pathol. 182 (1997) 128-137
21. Jawhari A., Jordan S., Poole S., Browne P., Pignatelli M., and Farthing M.J. Abnormal immunoreactivity of the E-cadherin-catenin complex in gastric carcinoma: relationship with patient survival. Gastroenterology 112 (1997) 46-54
22. Kase S., Sugio K., Yamazaki K., Okamoto T., Yano T., and Sugimachi K. Expression of E-cadherin and beta-catenin in human non-small cell lung cancer and the clinical significance. Clin. Cancer Res. 6 (2000) 4789-4796
23. Koga T., Hashimoto S., Sugio K., Yoshino I., Nakagawa K., Yonemitsu Y., et al. Heterogeneous distribution of P53 immunoreactivity in human lung adenocarcinoma correlates with MDM2 protein expression, rather than with P53 gene mutation. Int. J. Cancer 95 (2001) 232-239
24. Kotsinas A., Evangelou K., Zacharatos P., Kittas C., and Gorgoulis V.G. Proliferation, but not apoptosis, is associated with distinct beta-catenin expression patterns in non-small-cell lung carcinomas: relationship with adenomatous polyposis coli and G(1)-to S-phase cell-cycle regulators. Am. J. Pathol. 161 (2002) 1619-1634
25. Kratzke R.A., Greatens T.M., Rubins J.B., Maddaus M.A., Niewoehner D.E., Niehans G.A., et al. Rb and p16INK4a expression in resected non-small cell lung tumors. Cancer Res. 56 (1996) 3415-3420
26. Kudo Y., Kitajima S., Ogawa I., Hiraoka M., Sargolzaei S., Keikhaee M.R., et al. Invasion and metastasis of oral cancer cells require methylation of E-cadherin and/or degradation of membranous beta-catenin. Clin. Cancer Res. 10 (2004) 5455-5463
27. Kypta R.M., Su H., and Reichardt L.F. Association between a transmembrane protein tyrosine phosphatase and the cadherin-catenin complex. J. Cell Biol. 134 (1996) 1519-1529
28. Lee Y.C., Wu C.T., Chen C.S., and Chang Y.L. E-cadherin expression in surgically-resected non-small cell lung cancers-a clinicopathological study. Thorac. Cardiovasc. Surg. 48 (2000) 294-299
29. Lee Y.C., Wu C.T., Chen C.S., Hsu H.H., and Chang Y.L. The significance of E-cadherin and alpha-, beta-, and gamma-catenin expression in surgically treated non-small cell lung cancers of 3 cm or less in size. J. Thorac. Cardiovasc. Surg. 123 (2002) 502-507
30. Liu D., Huang C., Kameyama K., Hayashi E., Yamauchi A., Kobayashi S., et al. E-cadherin expression associated with differentiation and prognosis in patients with non-small cell lung cancer. Ann. Thorac. Surg. 71 (2001) 949-955
31. Martin B., Paesmans M., Mascaux C., Berghmans T., Lothaire P., Meert A.P., et al. Ki-67 expression and patients survival in lung cancer: systematic review of the literature with meta-analysis. Br. J. Cancer 91 (2004) 2018-2025
32. Matsuo Y., Hashimoto S., Koga T., Yonemitsu Y., Yoshino I., Sugimachi K., et al. Growth pattern correlates with the distribution of basement membrane and prognosis in lung adenocarcinoma. Pathol. Res. Pract. 200 (2004) 517-529
33. Mitsudomi T., Hamajima N., Ogawa M., and Takahashi T. Prognostic significance of p53 alterations in patients with non-small cell lung cancer: a meta-analysis. Clin. Cancer Res. 6 (2000) 4055-4063
34. Mori S., Ito G., Usami N., Yoshioka H., Ueda Y., Kodama Y., et al. p53 apoptotic pathway molecules are frequently and simultaneously altered in nonsmall cell lung carcinoma. Cancer 100 (2004) 1673-1682
35. Nakamura Y. Cleaning up on beta-catenin. Nat. Med. 3 (1997) 499-500
36. Nakanishi Y., Ochiai A., Akimoto S., Kato H., Watanabe H., Tachimori Y., et al. Expression of E-cadherin, alpha-catenin, beta-catenin and plakoglobin in esophageal carcinomas and its prognostic significance: immunohistochemical analysis of 96 lesions. Oncology 54 (1997) 158-165
37. Nelson W.J., and Nusse R. Convergence of Wnt, beta-catenin, and cadherin pathways. Science 303 (2004) 1483-1487
38. Niklinski J., Niklinska W., Laudanski J., Chyczewska E., and Chyczewski L. Prognostic molecular markers in non-small cell lung cancer. Lung Cancer 34 (2001) S53-S58
39. Oyama T., Kanai Y., Ochiai A., Akimoto S., Oda T., Yanagihara K., et al. A truncated beta-catenin disrupts the interaction between E-cadherin and alpha-catenin: a cause of loss of intercellular adhesiveness in human cancer cell lines. Cancer Res. 54 (1994) 6282-6287
40. Pirinen R.T., Hirvikoski P., Johansson R.T., Hollmen S., and Kosma V.M. Reduced expression of alpha-catenin, beta-catenin, and gamma-catenin is associated with high cell proliferative activity and poor differentiation in non-small cell lung cancer. J. Clin. Pathol. 54 (2001) 391-395
41. Ramasami S., Kerr K.M., Chapman A.D., King G., Cockburn J.S., and Jeffrey R.R. Expression of CD44v6 but not E-cadherin or beta-catenin influences prognosis in primary pulmonary adenocarcinoma. J. Pathol. 192 (2000) 427-432
42. Ray J.M., and Stetler-Stevenson W.G. The role of matrix metalloproteases and their inhibitors in tumour invasion, metastasis and angiogenesis. Eur. Respir. J. 7 (1994) 2062-2072
43. Retera J.M., Leers M.P., Sulzer M.A., and Theunissen P.H. The expression of beta-catenin in non-small-cell lung cancer: a clinicopathological study. J. Clin. Pathol. 51 (1998) 891-894
44. Reuning U., Magdolen V., Wilhelm O., Fischer K., Lutz V., Graeff H., et al. Multifunctional potential of the plasminogen activation system in tumor invasion and metastasis. Int. J. Oncol. 13 (1998) 893-906
45. Sherr C.J., and McCormick F. The RB and p53 pathways in cancer. Cancer Cell 2 (2002) 103-112
46. Shibanuma H., Hirano T., Tsuji K., Wu Q., Shrestha B., Konaka C., et al. Influence of E-cadherin dysfunction upon local invasion and metastasis in non-small cell lung cancer. Lung Cancer 22 (1998) 85-95
47. Shimoyama Y., Nagafuchi A., Fujita S., Gotoh M., Takeichi M., Tsukita S., et al. Cadherin dysfunction in a human cancer cell line: possible involvement of loss of alpha-catenin expression in reduced cell-cell adhesiveness. Cancer Res. 52 (1992) 5770-5774
48. Smythe W.R., Williams J.P., Wheelock M.J., Johnson K.R., Kaiser L.R., and Albelda S.M. Cadherin and catenin expression in normal bronchial epithelium and non-small cell lung cancer. Lung Cancer 24 (1999) 157-168
49. Steels E., Paesmans M., Berghmans T., Branle F., Lemaitre F., Mascaux C., et al. Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysis. Eur. Respir. J. 18 (2001) 705-719
50. Takeichi M. Cadherin cell adhesion receptors as a morphogenetic regulator. Science 251 (1991) 1451-1455
51. Wang Y.C., Lin R.K., Tan Y.H., Chen J.T., Chen C.Y., and Wang Y.C. Wild-type p53 overexpression and its correlation with MDM2 and p14ARF alterations: an alternative pathway to non-small-cell lung cancer. J. Clin. Oncol. 23 (2005) 154-164
52. WHO. International Histological Classification of Tumors, Histological Typing of Lung and Pleural Tumor. third ed. (1999), WHO, Geneva